Subscribe Us

header ads

Recents

header ads

Cancer Therapeutics Market Size, Growth, Demands Outlook and Forecasts to 2030

Precedence Research - January 25, 2023

According to the research report, the global cancer therapeutics market size is expected to touch USD 365.99 Billion by 2030, from USD 181.59 Billion in 2022, growing with a significant CAGR of 9.1% from 2022 to 2030. 

Cancer Therapeutics Market Size 2022 to 2030

The cancer therapeutics report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global cancer therapeutics in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global cancer therapeutics market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global cancer therapeutics during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1546

 Scope of the Cancer Therapeutics Market

Report CoverageDetails
Market SizeUS$ 365.99 Billion by 2030
Growth Rate from 2022 to 2030CAGR of 9.1%
Largest MarketNorth America
Fastest Growing MarketAsia Pacific
Base Year2021
Forecast Period2022 to 2030
Segments CoveredTop Selling Drug, Application, End User, Region

This study covers a detailed segmentation of the global cancer therapeutics market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global cancer therapeutics market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • AbbVie, Inc.
  • Johnson & Johnson
  • Celgene Corporation
  • AstellasPharma, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Merck KGaA
  • Eli Lilly and Company

Market Segmentation

 By Application

  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Cervical Cancer
  • Head and Neck Cancer
  • Glioblastoma
  • Malignant Meningioma
  • Mesothelioma
  • Melanoma
  • Others

By Top Selling Drugs

  • Revlimid
  • Avastin
  • Herceptin
  • Rituxan
  • Opdivo
  • Gleevec
  • Velcade
  • Imbruvica
  • Ibrance
  • Zytiga
  • Alimta
  • Xtandi
  • Tarceva
  • Perjeta
  • Temodar
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Cancer and Radiation Therapy Centers

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global cancer therapeutics report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global cancer therapeutics market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Therapeutics Market 

5.1. COVID-19 Landscape: Cancer Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Therapeutics Market, By Top Selling Drugs

8.1. Cancer Therapeutics Market, by Top Selling Drugs Type, 2021-2030

8.1.1. Revlimid

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Avastin

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Herceptin

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Rituxan

8.1.4.1. Market Revenue and Forecast (2019-2030)

8.1.5. Opdivo

8.1.5.1. Market Revenue and Forecast (2019-2030)

8.1.6. Gleevec

8.1.6.1. Market Revenue and Forecast (2019-2030)

8.1.7. Velcade

8.1.7.1. Market Revenue and Forecast (2019-2030)

8.1.8. Imbruvica

8.1.8.1. Market Revenue and Forecast (2019-2030)

8.1.9. Ibrance

8.1.9.1. Market Revenue and Forecast (2019-2030)

8.1.10. Zytiga

8.1.10.1. Market Revenue and Forecast (2019-2030)

8.1.11. Alimta

8.1.11.1. Market Revenue and Forecast (2019-2030)

8.1.12. Xtandi

8.1.12.1. Market Revenue and Forecast (2019-2030)

8.1.13. Tarceva

8.1.13.1. Market Revenue and Forecast (2019-2030)

8.1.14. Perjeta

8.1.14.1. Market Revenue and Forecast (2019-2030)

8.1.15. Temodar

8.1.15.1. Market Revenue and Forecast (2019-2030)

8.1.16. Others

8.1.16.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Cancer Therapeutics Market, By Application

9.1. Cancer Therapeutics Market, by Application, 2021-2030

9.1.1. Blood Cancer

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Lung Cancer

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Colorectal Cancer

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Prostate Cancer

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Breast Cancer

9.1.5.1. Market Revenue and Forecast (2019-2030)

9.1.6. Cervical Cancer

9.1.6.1. Market Revenue and Forecast (2019-2030)

9.1.7. Head and Neck Cancer

9.1.7.1. Market Revenue and Forecast (2019-2030)

9.1.8. Glioblastoma

9.1.8.1. Market Revenue and Forecast (2019-2030)

9.1.9. Malignant Meningioma

9.1.9.1. Market Revenue and Forecast (2019-2030)

9.1.10. Mesothelioma

9.1.10.1. Market Revenue and Forecast (2019-2030)

9.1.11. Melanoma

9.1.11.1. Market Revenue and Forecast (2019-2030)

9.1.12. Others

9.1.12.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Cancer Therapeutics Market, By End User 

10.1. Cancer Therapeutics Market, by End User, 2021-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Specialty Clinics

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Cancer and Radiation Therapy Centers

10.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Cancer Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.1.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.3. Market Revenue and Forecast, by End User (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.2.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.6.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.7.3. Market Revenue and Forecast, by End User (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.3.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.6.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.7.3. Market Revenue and Forecast, by End User (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.6.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.7.3. Market Revenue and Forecast, by End User (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Top Selling Drugs (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.5.3. Market Revenue and Forecast, by End User (2019-2030)

Chapter 12. Company Profiles

12.1. F. Hoffmann-La Roche AG

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bristol-Myers Squibb Company

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. AbbVie, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Johnson & Johnson

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Celgene Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. AstellasPharma, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Pfizer, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Novartis AG

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Merck KGaA

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Eli Lilly and Company

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

Tags:

Post a Comment

0 Comments